NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) on behalf of DexCom stockholders. Our investigation concerns whether DexCom has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On July 25, 2024, after the closure of market trading, DexCom issued a press ...

Dexcom shares sank more than 40% on Friday and headed for their worst day ever after the diabetes management company reported disappointing revenue for the second quarter and offered weak guidance. The stock fell $45.38 to $62.47 as of early afternoon, wiping out about $18 billion in market cap. Prior to Friday, the biggest drop came in September 2017, when the shares plunged 33% in a day. Dexcom held its stock market debut in 2005.Dexcom's revenue increased 15% to $1 billion from $871.3 million a year earl ...

DexCom, Inc. (DXCM) reported second-quarter 2024 adjusted earnings per share (EPS) of 43 cents, which beat the Zacks Consensus Estimate of 39 cents by 18.5%. The company had reported earnings of 34 cents per share in the prior-year quarter.DXCM registered GAAP net income per share of 35 cents, up from the year-ago quarter’s figure of 28 cents.Revenue DetailsTotal revenues grew 15% (16% on an organic basis) to $1 billion on a year-over-year basis but missed the Zacks Consensus Estimate by 3.8%. The strong re ...

Investors are worried about the diabetes care technology leader's slowing growth.Shares of DexCom (DXCM -40.46%) were crashing 39.9% lower as of 10:20 a.m. ET on Friday. The huge sell-off came after the continuous glucose monitoring (CGM) systems maker announced its second-quarter results following the market close on Thursday.DexCom's revenue increased 15% year over year in Q2 to $1 billion. However, that came in a little below the average revenue estimate of $1.04 billion based on LSEG's survey of analyst ...

Dexcom (NASDAQ:DXCM) stock is down over 40% after reporting disappointing revenue for the second quarter.It also lowered guidance for the rest of the year.The problem lies with its Stelo continuous glucose monitor. The company is delaying the device’s launch as it builds inventory.Dexcom earned $143.5 million, 35 cents per share fully diluted, on revenue of $1 billion. But it guided toward slower growth, just 1% to 3% for the third quarter, and 11% to 13% for the year.DXCM stock opened this morning at about ...

NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into DexCom, Inc. (NASDAQ: DXCM) for potential violations of the federal securities laws. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Why Did DexCom’s Stock Drop? DexCom develops glucose monitoring systems for diabetes management. The company discussed how its recent sales force re ...

SAN DIEGO, July 26, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether DexCom, Inc. (NASDAQ: DXCM) or any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws. What if I purchased DexCom securities? If you purchased securities and suffered losses on you ...

DexCom (NASDAQ:DXCM) stock is falling on Friday after the company released its earnings report for Q2 2024.DexCom starts its earnings report with adjusted earnings per share of 43 cents. That’s better than Wall Street’s estimate of 39 cents per share. It’s also an improvement over its adjusted EPS of 34 cents in the same period of the year prior.However, the company’s revenue of $1 billion failed to impress. It doesn’t stack up to analysts’ estimate of $1.04 billion. Even if its a 15% increase year-over-yea ...

U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Friday.Shares of DexCom, Inc. DXCM fell sharply during Friday's pre-market trading after the company reported worse-than-expected second-quarter revenue results and issued weak FY24 revenue guidance.DexCom reported quarterly earnings of 43 cents per share, which beat the analyst consensus estimate of 39 cents. Quarterly sales came in at $1.004 billion which missed the analyst consensus estimate of $1.036 billion.D ...

martin-dm/E+ via Getty Images Investment Thesis DexCom (NASDAQ:DXCM) reported one of the most disappointing Q2 earnings reports of this earnings season, with the company missing its estimates by 4% on the top end while managing to edge past the market's EPS expectations set for DexCom. This was a rare and shocking miss for the San Diego, CA-headquartered company, which reported a puzzling slowdown in sales in the U.S. market, still faring better than its sales in its international markets outside the U.S., ...